CASI Pharmaceuticals, Inc.
CASIF
$0.13
-$0.01-4.59%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.71M | 26.85M | 31.56M | 31.37M | 28.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.71M | 26.85M | 31.56M | 31.37M | 28.54M |
| Cost of Revenue | 10.64M | 17.24M | 18.61M | 18.41M | 17.39M |
| Gross Profit | 10.08M | 9.61M | 12.95M | 12.96M | 11.15M |
| SG&A Expenses | 46.61M | 44.42M | 45.49M | 44.81M | 41.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | -2.00K | -2.00K | -7.00K | -2.00K |
| Total Operating Expenses | 63.56M | 70.39M | 72.95M | 71.59M | 67.75M |
| Operating Income | -42.85M | -43.55M | -41.39M | -40.23M | -39.21M |
| Income Before Tax | -48.05M | -49.38M | -46.89M | -40.48M | -39.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.05 | -49.38 | -46.89 | -40.48 | -39.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.05M | -49.38M | -46.89M | -40.48M | -39.26M |
| EBIT | -42.85M | -43.55M | -41.39M | -40.23M | -39.21M |
| EBITDA | -40.78M | -41.22M | -38.70M | -37.19M | -35.82M |
| EPS Basic | -2.72 | -2.98 | -2.86 | -2.51 | -2.53 |
| Normalized Basic EPS | -1.15 | -1.25 | -1.22 | -1.65 | -1.67 |
| EPS Diluted | -2.72 | -2.99 | -2.86 | -2.51 | -2.53 |
| Normalized Diluted EPS | -1.15 | -1.25 | -1.22 | -1.65 | -1.67 |
| Average Basic Shares Outstanding | 74.15M | 66.20M | 65.44M | 63.46M | 61.35M |
| Average Diluted Shares Outstanding | 74.15M | 66.20M | 65.44M | 63.46M | 61.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |